1 / 11

Pharmaceutical Research in the NHS: at what cost?

Pharmaceutical Research in the NHS: at what cost?. Ignazio Di Giovanna, Chair of the Institute of Clinical Research, Director CCA 2000 Ltd. Working Group. Sept 03 National R&D Forum ’Working with Industry’ working group Chaired by Maria Palmer

morgan
Download Presentation

Pharmaceutical Research in the NHS: at what cost?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pharmaceutical Research in the NHS: at what cost? Ignazio Di Giovanna, Chair of the Institute of Clinical Research, Director CCA 2000 Ltd

  2. Working Group • Sept 03 • National R&D Forum ’Working with Industry’ working group • Chaired by Maria Palmer • Director of Research and Clinical Effectiveness • United Bristol Healthcare NHS Trust • 1st meeting was on 19th November 2003

  3. Aims of the Working Group • To enable participants to understand the cost structure of a clinical trial, i.e. to define the types of costs associated with a trial such as staff time, cost of procedures, overheads etc. • To discuss and define the considerations NHS R&D must make when costing a trial.

  4. Aims of the Working Group • To help participants better understand how Sponsors calculate costs and where the NHS can accept these. • To discuss how costs are defined and calculated, but NOT to benchmark clinical trial costs either for the NHS or Sponsor. • To develop a model for costing clinical research for use by NHS organisations.

  5. ‘AE’…..of the Working Group • “Advantageous Experience” • To Help Industry develop a greater awareness and understanding of the role of NHS R&D Offices.

  6. Working Group Members • NHS R&D Forum • NHS • University • Industry • Department of Health • Assoc. of the British Pharmaceutical Industry • Institute of Clinical Research

  7. Working Group • Maria Palmer (Chair); United Bristol Healthcare NHS Trust • R&D Forum • Janet Messer • University (University of Wales College of Medicine) • Professor Keith Harding • John Zajicek

  8. United Bristol Healthcare NHS Trust Christine McGrath Teresa Smith Jacqueline Briggs Avon and Wiltshire NHS Trust Tony Soteriou Robert Priday Cardiff and Vale NHS Trust David Powell Helen Harris Stuart Bodman Gloucestershire Hospitals NHS Trust Julie Hapeshi Robert Neale Plymouth Hospitals NHS Trust Peter Bendle Royal Devon and Exeter Healthcare Trust Rosemary Sowden Southampton University Hospitals Trust Di Sheridan Vanessa Rees Working Group - NHS

  9. Industry Covance CAPS Ltd Graham Ilsley GlaxoSmithKline Kaye Hallett Adrienne Clarke Infonetica Ltd Jon Bell Jon Thorne Novartis Pharmaceuticals Karen Hollander Katie Kennedy Roger Newbery Working Group

  10. Working Group Members • Department of Health • Mark Lewis • Association of the British Pharmaceutical Industry (ABPI) • Richard Tiner • Institute of Clinical Research • Ignazio Di Giovanna (Also of CCA2000 Ltd)

  11. Professor Tony Howell Christie Hospital in Manchester.

More Related